title: Pharmacogenetics of P450 oxidoreductase:  implications in drug metabolism and therapy.
abstract: The redox reaction of cytochrome P450 enzymes (CYP) is an important physiological and biochemical reaction in the human body, as it is involved in the oxidative metabolism of both endogenous and exogenous substrates. Cytochrome P450 oxidoreductase (POR) is the only obligate electron donor for all of the hepatic microsomal CYP enzymes. It plays a crucial role in drug metabolism and treatment by not only acting as an electron donor involved in drug metabolism mediated by CYP enzymes but also by directly inducing the transformation of some antitumor precursors. Studies have found that the gene encoding human POR is highly polymorphic, which is of considerable clinical significance as it affects the metabolism and curative effects of clinically used drugs. This review aims to discuss the effect of POR and its genetic polymorphisms on drug metabolism and therapy, as well as the potential mechanisms of POR pharmacogenetics.
authors.affiliation: Hunan Key Laboratory of Pharmacogenetics, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, People's Republic of China.
authors.forename: Lei
authors.initials: L
authors.lastname: Hu
authors.forename: Wei
authors.initials: W
authors.lastname: Zhuo
authors.forename: Yi-Jing
authors.initials: YJ
authors.lastname: He
authors.forename: Hong-Hao
authors.initials: HH
authors.lastname: Zhou
authors.forename: Lan
authors.initials: L
authors.lastname: Fan
mesh_terms: D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics; D008099:Liver / Q000378:metabolism; D009251:NADPH-Ferrihemoprotein Reductase / Q000235:genetics*; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
chemical_list: D004364:Pharmaceutical Preparations; D009251:NADPH-Ferrihemoprotein Reductase